Zain Ebrahim
Stock Analyst at J.P. Morgan
(1.92)
# 3,312
Out of 5,020 analysts
38
Total ratings
65%
Success rate
0.7%
Average return
Main Sectors:
Stocks Rated by Zain Ebrahim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LON: GSK GSK plc | Reiterated: Sell | 1,700p | 1,795p | -5.29% | 29 | Oct 1, 2026 | |
| SWX: BANB Bachem Holding AG | Reiterated: Buy | CHF 85.00 → CHF 90.00 | CHF 78.75 | +14.29% | 4 | Sep 10, 2026 | |
| EPA: EAPI Euroapi S.A. | Reiterated: Hold | €1.70 | €0.73 | +131.92% | 1 | May 13, 2026 | |
| LON: HIK Hikma Pharmaceuticals PLC | Reiterated: Buy | 2,400p → 2,000p | 1,571p | +27.31% | 2 | Mar 3, 2026 | |
| LON: OXB Oxford Biomedica plc | Reiterated: Hold | 550p | 509p | +8.06% | 1 | Dec 8, 2025 | |
| SWX: LONN Lonza Group AG | Reiterated: Buy | CHF 675.00 | CHF 560.60 | n/a | 1 | Jul 28, 2025 |
GSK plc
Oct 1, 2026
Reiterated: Sell
Price Target: 1,700p
Current: 1,795p
Upside: -5.29%
Bachem Holding AG
Sep 10, 2026
Reiterated: Buy
Price Target: CHF 85.00 → CHF 90.00
Current: CHF 78.75
Upside: +14.29%
Euroapi S.A.
May 13, 2026
Reiterated: Hold
Price Target: €1.70
Current: €0.73
Upside: +131.92%
Hikma Pharmaceuticals PLC
Mar 3, 2026
Reiterated: Buy
Price Target: 2,400p → 2,000p
Current: 1,571p
Upside: +27.31%
Oxford Biomedica plc
Dec 8, 2025
Reiterated: Hold
Price Target: 550p
Current: 509p
Upside: +8.06%
Lonza Group AG
Jul 28, 2025
Reiterated: Buy
Price Target: CHF 675.00
Current: CHF 560.60
Upside: n/a